Understanding how Candida glabrata becomes resistant to antifungal medications
Official title: Translational Regulation of Candida glabrata Azole Resistance
Funded at University of Texas Hlth Science Center · NIH-10766810 · Data updated 2026-11-12
This study is looking into why the fungus Candida glabrata can resist treatment with certain antifungal medications, especially in patients with weakened immune systems, to help find better ways to fight these infections.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | January 20, 2023 |
| Project end | December 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $232,500 |
| NIH project number | 5R21AI172207-02 |
| Project ID | NIH-10766810 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include immunocompromised individuals, such as those with AIDS, cancer patients undergoing chemotherapy, and organ transplant recipients.
✕Less likely to help
Patients with infections caused by other types of fungi or those who are not immunocompromised may not benefit from this research.
What this research studies
This research investigates the mechanisms behind the resistance of Candida glabrata, a harmful fungus that can cause serious infections in immunocompromised patients. The study focuses on how certain genetic and translational factors contribute to this resistance, particularly in relation to azole antifungal drugs. By analyzing the genetic makeup and expression patterns of the fungus, researchers aim to uncover new insights that could lead to better treatment options for affected patients.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients suffering from infections caused by Candida glabrata.
How similar studies have gone: Previous research has shown success in understanding antifungal resistance mechanisms in other fungi, suggesting that this approach may yield valuable insights.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Kadosh, David — University of Texas Hlth Science Center
- Study coordinator: Kadosh, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.